BruceAndrewSalzbergMD

PubMed

• Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.
  Hans H Herfarth, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla
  Clinical and Translational Gastroenterology. 2024-03-01
• 13 citations
  Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
  Millie D Long, Anita Afzali, Monika Fischer, David Hudesman, Maisa Abdalla
  Inflammatory Bowel Diseases. 2023-04-03
• 47 citations
  Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report.
  Gary R. Lichtenstein, Brian G. Feagan, Uma Mahadevan, Bruce Salzberg, Wayne Langholff
  The American Journal of Gastroenterology. 2018-07-19

Journal Articles

• Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report  
  Russell D Cohen, Uma Mahadevan, Bruce A Salzberg, Gary R Lichtenstein, William J Sandborn, Michael Safdi, Nature
• Five-Year Efficacy and Safety Analysis of the Adenoma Prevention with Celecoxib Trial  
  Bertagnolli, M., Salzberg, B., et al, Cancer Prevention Research Journal, 1/1/2009
• Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis  
  Baumgart, D., Salzberg, B., et al, Inflammatory Bowel Diseases, 1/1/2009
• APC Study Investigators Celecoxib for the prevention of sporadic colorectal adenomas  
  Bertagnolli, M., Salzberg, B., et al, New England Journal of Medicine, 1/1/2006
• Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease  
  Lichtenstein, G., Salzberg, Bruce A., et al, American Journal of Gastroenterology, 1/1/2006
• Serious Infections and Mortality in Association With Therapies for Crohn�s Disease: TREAT Registry  
  Lichtenstein, G., Salzberg, B., et al, Clinical Gastroenterology and Hepatology, 1/1/2006
• A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-a, in patients with corticosteroid-dependent ...  
  Feagan, B. G, Salzberg, B., et al, Alimentary Pharmacology & Therapeutics, 1/4/2005
• A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Engineered Human Anti-Body to TNF (CDP571) for Steroid Sparing and Maintenance of Remission i...  
  Feagan, B., Sandborn, W., Hanauer, S., Salzberg, B., et al, Gastroenterology, 1/1/2000
• Double-Blinded Randomized, Placebo-Controlled, Trial of the Remission Inducing and Steroid Sparing Properties of Two Schedules of ISIS 2302 (ICAM-1 Antisense) in Activ...  
  Yacyshyn, B., Chey, W., Salzberg, B., et al, Gastroenterology, 1/1/2000
• Treat Registry: Examination of the Long-Term Impact of Various Crohn�s Disease Treatment Regimens  
  Sandborn, W., Lichtenstein, G., Hanauer, S., Salzberg, B., et al, Gastroenterology, 1/1/2000
• 6-mercaptopurine and prednisone for newly diagnosed pediatric Crohn's disease: a prospective multi-center placebo controlled trial  
  Markowitz, J., Salzberg, B., et al, Gastroenterology, 1/1/1998
• A Multi-Center, Double-Blind Dose Response Trial of Colazide (R) (balsalazide disodium) and Asacol (R) (mesalamine) for Mild-Moderately Active Ulcerative Colitis  
  Levine, D.S., Pruitt R., Salzberg, B., et al, Gastroenterology, 1/1/1997
• Zileuton, a 5-Lipoxygenase Inhibitor in the treatment of Active Ulcerative Colitis: A double blind, placebo controlled trial  
  Peppercorn K., Das C., Elson, Salzberg B., et al, Gastroenterology, 1/1/1993
• Join now to see all

Abstracts/Posters

• Safety of Infliximab in Crohn�s Disease Data from the TREAT Registry.
  Lichtenstein, G., Salzberg, B., Cohen,R., et al, UEGW, Prague, Czech Republic, 1/1/2004
• Successful One Hour Infusion of Infliximab for Crohn�s Disease Patients in an Outpatient Setting.
  Salzberg, B., Kendall , K., DDW, 1/1/2004
• A Humanized Anti-CD3 Monoclonal Antibody, Visilizumab, for Treatment of Severe Steroid-Refractory Ulcerative Colitis: Preliminary results of a Phase I Study
  Plevy, S., Salzberg, B., Regueiro, M., Sandborn, W., Hanauer, S., Targan, S., Mayer, L., Lowder, J., DDW, Orlando, FL, 1/1/2003
• A Double-Blind Placebo-Controlled Pilot Study of the Safety and Activity of Interleukin-10 in the Prevention of Acute Pancreatits Following ERCP
  Epstein, M., Salzberg B., et al, ACG, 1/1/2001
• Efficacy of Anti-TNF Therapy in Patients with Ulcerative Colitis
  Su, C., Salzberg, B., et al, ACG, 1/1/2001
• Join now to see all

Lectures

• Remicade Therapy �Transcending conventional therapy in Crohn�s Disease Patients" 
  Multiple Locations, 2003, 2004, 2005, 2007 - 1/1/2007
• Crohn�s Disease State of the Art 
  Tokyo, Japan - 1/1/2002
• Ulcerative Colitis �The American Way� 
  Istanbul, Turkey - 1/1/2001
• Gastro esophageal Reflux and Sleep Disorders 
  Northside Hospital, Atlanta, GA, 1994, 1995, 1996, 1997, 1998, 1999, 2000 - 1/1/2000
• Remicade �To Treat or to Retreat� Update of ACCENT I data 
  1/1/1999
• Setting Up an Infusion Suite in Your Office - Boston 
  Los Angeles, CA - 1/1/1999
• Treatment of Patients with Moderate to Severe Crohn�s Disease 
  1/1/1999
• Non-Cardiac Chest Pain/Esophageal Spasm 
  Northside Hospital, Atlanta, GA - 1/1/1995
• Ulcerative Colitis - General Overview 
  Atlanta, GA - 1/1/1995
• Flexible Sigmoidoscopy for the Internist 
  Atlanta, GA, 1991, 1992, 1993, 1994 - 1/1/1994
• Inflammatory Bowel disease, �Facts for your Family" 
  Atlanta, GA, 1992, 1994 - 1/1/1994
• Gastric bubble for Obese Patients 
  Fort Lauderdale, FL - 1/1/1983
• Gastric Cytoprotection 
  Columbus, GA
• Intravenous Hyper alimentation complications 
  St. Joseph�s Hospital Atlanta, GA
• New Horizons in the Management of Gallstones 
  Multiple Locations
• Join now to see all

Other

• Delivering patient care the American way (brochure) 
  Salzberg B, Progressing the Management of Ulcerative Colitis
  1/1/2001